Ultrasound insonification of microbubbles has been shown to increase vascular permeability to locally enhance drug delivery. For more effective and controllable therapeutic outcomes, uniform acoustic responses from microbubbles and a deeper understanding of the biophysical mechanisms of drug delivery are critical. In this study, we investigated the impact of monodisperse microbubble size and their dynamics on cellular responses and drug delivery outcomes in endothelial cells. Monodisperse microbubbles with radii of 1.5, 2.2, 2.7, and 2.9 μm were produced using a microfluidic flow-focusing device. Upon insonification (2 MHz, 220 kPa peak negative pressure, 10 cycles), the microbubble oscillation was captured in real-time at 10 million frames per second using ultra-high-speed imaging, while confocal microscopy was employed to observe cellular responses in both 2D and 3D. For the 65 microbubbles studied, the 2.2 μm microbubbles, i.e., corresponding to the resonant radius at 2 MHz ultrasound, exhibited the highest sonoporation rate (75 %), induced the largest membrane perforations (a median value of 78 μm2) and highest intracellular drug uptake. The 1.5 μm microbubbles achieved a comparable sonoporation rate (73 %), yet with significantly smaller membrane perforations (a median value of 20 μm2), lower intracellular drug uptake, and highest occurrence of transendothelial drug delivery pathways (64 %). Mechanistically, microbubble-generated shear stress was identified as the significant factor driving sonoporation, while normal stress did not show significance. In conclusion, our study highlights the importance of carefully selecting the microbubbles size to maximize microbubble-mediated drug delivery outcomes and facilitate safe translation of monodisperse microbubbles into clinical practice.

Monodisperse microbubbles have demonstrated significant potential in enhancing the efficacy of ultrasound contrast agents for both imaging and therapeutic applications. These microbubbles can be directly produced using a microfluidic flow-focusing method, which allows precise control over their size. However, preventing coalescence during production remains a critical challenge. While elevated production temperatures (e.g., 55 °C) can suppress coalescence, such conditions complicate microfluidic device design and may be incompatible with targeting agents and drug conjugates. This protocol outlines a method for producing monodisperse phospholipid-coated microbubbles at room temperature, with the microbubbles' stability and monodispersity maintained for at least 7 days. The protocol also describes the fabrication of reusable PDMS microfluidic chips and preparation of the phospholipid coating formulation containing the surfactant Pluronic F68. Our findings show that the microbubbles produced using this method maintain their size and stability over 7 days, supporting their future applicability in clinical settings where stable and controllable ultrasound contrast agents are essential.

Ultrasound contrast agents, comprised of phospholipid-coated microbubbles, can be produced as monodisperse populations using a microfluidic flow-focusing device. However, microbubble coalescence remains a significant challenge. High production temperatures (e.g. 55° C) can be used to suppress coalescence, but it complicates the microfluidic device design and is incompatible with targeting agents and drug conjugates. This study investigates the production of monodisperse microbubbles at room temperature with the addition of the amphiphilic surfactant Pluronic F68. Two 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)-based phospholipid formulations were investigated: F1, containing 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[carbonyl-methoxypolyethylene glycol] (DPPE-PEG5000), and F2, which included both DPPE-PEG5000 and polyoxyethylene(40) stearate (PEG40-stearate). We characterized the size stability and acoustic behavior of monodisperse microbubbles produced with various Pluronic F68 concentrations. Adding 5-10 mol% Pluronic F68 was found to effectively suppress coalescence and facilitated the production of monodisperse microbubbles that remained shelf stability for at least 7 days. Acoustic attenuation measurements revealed a shell stiffness ranging from 0.78 to 0.93 N/m for these microbubbles. The 10 mol% Pluronic F68 addition (10PF) demonstrated superior monodispersity and was selected for further experiments. Upon dilution, the size and resonance frequencies of both F1-10PF and F2-10PF decreased over time, though F2-10PF showed better stability compared to F1-10PF for both metrics. Both F1-10PF and F2-10PF exhibited a stronger subharmonic scattering intensity than SonoVue (clinical approved microbubbles), which offers potential for blood pressure sensing. Our study shows that incorporating Pluronic F68 facilitates the production of monodisperse microbubbles at room temperature that are stable long-term and have excellent acoustical properties, with the F2-10PF formulation demonstrating better stability than the F1-10PF.

Photocatalytic degradation of toxic organic pollutants using natural sunlight is a rapidly advancing area of research, particularly involving binary or ternary component photocatalysts with Z-type heterojunctions. In this study, ternary g-C3N4/BiOBr/Bi2MoO6 photocatalysts were fabricated using a simple one-pot solvothermal method. The morphology and physicochemical properties of the samples were characterized using various techniques, including X-ray diffraction analysis (XRD), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), transmission electron microscopy (TEM) and X-ray photoelectron spectroscopy (XPS), confirming the presence of BiOBr, Bi2MoO6, and g-C(3)N(4 )components. The inclusion of g-C(3)N(4 )increased the BET surface area of the composite up to 46 m(2)/g, compared with BiOBr. In addition, g-C(3)N(4 )also enhanced the light absorption capability of the composite into the visible light range, while BiOBr and Bi2MoO6 significantly improved separation of electron-hole pairs, as evidenced by photoluminescence (PL) intensity. Under visible light illumination (LED lamp), the prepared photocatalyst showed high efficiency, achieving 94 % degradation of ciprofloxacin (CIP) antibiotic in 180 min and 92% degradation of Rhodamine B (RhB) dye in 240 min. Moreover, under natural sunlight irradiation, the photocatalyst achieved degradation efficiencies of approximately 91 % for CIP and 100% for RhB within 180 minutes. The photodegradation of the pollutants followed first-order kinetics with a Z-scheme type heterojunction. The photogenerated electrons played a crucial role as the main active species involved in detoxification of the organic contaminants. The photocatalyst exhibited excellent structural stability and good cycling ability, maintaining its original photocatalytic performance even after five cycles of use. This work demonstrates a promising strategy for developing sunlight-active ternary heterojunctions for environmental remediation.

As the microbubble's resonance frequency is size-dependent, polydisperse microbubbles induce varying drug delivery outcomes at one ultrasound frequency. This study aimed to investigate drug delivery outcome of monodisperse MBs (mMBs) with radii ranging from 1.5–2.9 μm insonified at 2 MHz. Phospholipid-coated mMBs were generated using the Horizon microfluidic flow-focusing device. In vitro experiments were conducted on single microbubble-endothelial cells (n = 68) using confocal microscopy and 10 Mfps ultra-high-speed imaging. At 220 kPa PNP for 10 cycles, the 1.5 μm mMBs exhibited the highest PI uptake in 81.3% of cases, followed by 77.3% for 2.2 μm, 36.8% for 2.7 μm and 13.3% for 2.9 μm mMBs. Conversely, the 1.5 μm mMBs had the second lowest excursion amplitude (R;max-R;0) of 0.8 ± 0.3 μm as this was 1.2 ± 0.3 μm for 2.2 μm mMBs, 1.0 ± 0.3 μm for 2.7 μm mMBs, and 0.7 ± 0.2 μm for 2.9 μm mMBs. Additionally, for the 1.5, 2.2, and 2.7 μm mMBs, PI uptake and tunnel formation occurred more often (1.6, 1.8, and 1.3 times, respectively) than PI uptake and a resealing membrane pore. During insonification, mMB pinch-off occurred more frequently in tunnel formation (70.8%) than resealing pore formation (53.3%). This research revealed the impact of mMBs size on drug delivery outcome.

Lipid-shelled microbubbles (MBs) offer potential as theranostic agents, capable of providing both contrast enhancement in ultrasound imaging as well as a route for triggered drug release and improved localized drug delivery. A common motif in the design of such therapeutic vehicles is the attachment of the drug carrier, often in the form of liposomes, to the microbubble. Traditionally, such attachments have been based around biotin-streptavidin and maleimide-PDP chemistries. Comparatively, the use of DNA-lipid tethers offers potential advantage. First, their specificity permits the construction of more complex architectures that might include bespoke combinations of different drug-loaded liposomes and/or targeting groups, such as affimers or antibodies. Second, the use of dual-lipid tether strategies should increase the strength of the individual tethers tethering the liposomes to the bubbles. The ability of cholesterol-DNA (cDNA) tethers for conjugation of liposomes to supported lipid bilayers has previously been demonstrated. For in vivo applications, bubbles and liposomes often contain a proportion of polyethylene glycol (PEG) to promote stealth-like properties and increase lifetimes. However, the associated steric effects may hinder tethering of the drug payload. We show that while the presence of PEG reduced the tethering affinity, cDNA can still be used for the attachment of liposomes to a supported lipid bilayer (SLB) as measured via QCM-D. Importantly, we show, for the first time, that QCM-D can be used to study the tethering of microbubbles to SLBs using cDNA, signified by a decrease in the magnitude of the frequency shift compared to liposomes alone due to the reduced density of the MBs. We then replicate this tethering interaction in the bulk and observe attachment of liposomes to the shell of a central MB and hence formation of a model therapeutic microbubble.

New strategy to create sunlight-active photocatalysts is a vital research topic in photocatalysis. In this work, ZnO/ZnS heterojunctions were fabricated very easily by thermal oxidation of hydrothermally grown ZnS in air. XRD, FT-IR, FESEM, TEM, XPS, XAS and PL results confirmed that ZnS-500 (ZnS calcined at 500 degrees C) contains the ZnO/ZnS heterojunctions. The ZnS-500 exhibited the highest photoactivity toward removal of azo dyes (reactive red 141, Congo red) and antibiotics (ofloxacin, norfloxacin) under natural sunlight. The combination of ZnS and ZnO enhances the photoactivity by suppressing the recombination of electron-hole pairs. The photodegradation of the organic contaminants followed pseudo-first order kinetics. The photocatalyst showed structural stability after five cycles. To understand the photocatalytic degradation mechanism, trapping experiment using various scavengers have been investigated. Photogenerated electrons are the crucial species involved in the degradation of the pollutant. It is also proposed that charge transfer at the ZnO/ZnS heterojunction is the Z-scheme type. This work provides a facile strategy for the interfacial engineering of heterojunctions with enhanced photocatalytic performance for environmental remediation.

Microbubble-mediated drug delivery using polydisperse microbubbles has shown differences in drug delivery outcome due to the microbubble’s differences in size and, thus, acoustic response. The aim of this study was to investigate whether monodisperse microbubbles can achieve controllable sonoporation and tunnel formation. Using the Horizon microfluidics platform, monodisperse phospholipid-coated microbubbles were produced with radii of 1.25–3.5 μm. Single microbubble-endothelial cell interactions (n = 82) upon insonification at 2 MHz (200 kPa PNP, 10 cycles) were investigated in vitro using confocal microscopy and ultra-high-speed imaging (10Mfps). No cellular response was observed for the 3.5 μm microbubbles having excursion amplitudes (Rmax-R0) ranging from 0.3 to 0.6 μm. PI uptake and resealing pores were observed more often for the 1.5 μm microbubbles (50%) with excursion amplitudes ranging from 0.5 to 0.9 μm than for the other microbubble sizes. PI uptake and tunnel formation was most observed for the 1.25 μm microbubbles (46.6%; 0.4–0.6 μm excursion amplitudes) and least for the 3 μm microbubbles (4.2%; 1.0 μm excursion amplitude). No other cellular responses were observed for the 3 μm microbubbles. The excursion ratio (Rmax-Rmin/R0) better separated the tunnel formation events (>0.6) from other cellular responses (0.1–0.6). This study shows the importance of monodisperse microbubbles for tuning drug delivery.

Traditional colloidal syntheses of metal nanoparticles (NPs) are highly sensitive to the selection of and quality of chemical reducing agents and metal precursors. To address these challenges, we demonstrate the complete sonoelectrochemical synthesis of monodisperse metal NPs starting from bulk metal, using Cu as a model system. Electrochemical syntheses of NPs are of great interest as the oxidation and reduction processes that account for product formation can occur directly at the anode and cathode, respectively. This ability has the potential to improve reproducibility by simplifying the chemical pathway to NPs, with electrosyntheses often also providing unique kinetic pathways toward green product formation. Herein, ultrasound is coupled with electrosynthesis to clean the electrode surface, dispersing the NPs produced at the electrode into solution. We were able to shift the size distribution to form monodispersed metal NPs through control of applied potential (Vapplied) and ultrasonic pulses. The synthesis begins with electrooxidation of bulk Cu metal to directly dissolve metal ions into a microemulsion system. This step is followed by sonoelectroreduction of the ions, which facilitates the formation of dispersible, monodisperse Cu NPs with diameters <10 nm. The size distribution can be controlled by adjusting the Vapplied, pulse intensity, and pulse sequence implemented during sonoelectroreduction. We view this technique as a scalable method to synthesize metal NPs from bulk metal without chemical reducing agents.

Microbubbles (MBs) have a multitude of applications including as contrast agents in ultrasound imaging and as therapeutic drug delivery vehicles, with further scope for combining their diagnostic and therapeutic properties (known as theranostics). MBs used clinically are commonly made by mechanical agitation or sonication methods, which offer little control over population size and dispersity. Furthermore, clinically used MBs are yet to be used therapeutically and further research is needed to develop these theranostic agents. In this paper, we present our MB production instrument "Horizon," which is a robust, portable, and user-friendly instrument, integrating the key components for producing MBs using microfluidic flow-focusing devices. In addition, we present the system design and specifications of Horizon and the optimized protocols that have so far been used to produce MBs with specific properties. These include MBs with tailored size and low dispersity (monodisperse); MBs with a diameter of ∼2 μm, which are more disperse but also produced in higher concentration; nanobubbles with diameters of 100-600 nm; and therapeutic MBs with drug payloads for targeted delivery. Multiplexed chips were able to improve production rates up to 16-fold while maintaining production stability. This work shows that Horizon is a versatile instrument with potential for mass production and use across many research facilities, which could begin to bridge the gap between therapeutic MB research and clinical use.

Nanomedicine has grown structurally complex in order to perform multiple tasks at a time. However, their unsatisfied reliability, uniformity and reproducibility account for the high rates of attrition in translational research. So far, most studies have been one-sidedly focused on the treatment efficacy of inorganic nanoparticles as cancer therapeutics, but overlook their elimination from the body - a key factor in getting regulatory approval. Instead of developing a new drug nanocarrier with uncertain future in medical practice, we therefore choose to leverage the utility of promising and translatable gold nanoclusters (AuNCs) for designing a simple but robust "all-in-one" nanocluster drug delivery system, where the AuNCs not only strengthen the renal clearance of neutral red (NR) as a model drug, but also aid its passive tumor targeting via the enhanced permeability and retention (EPR) effect. More interestingly, NR can stimulate the production of reactive oxygen species (ROS) to suppress tumor growth under ultralow-level radiation with a smartphone's torch (fluence rate: 8 mW/cm(2)). This finding is especially valuable to low-and middle-income countries lacking resources in healthcare settings. By means of first-principles simulations, we also study in-depth the energies, structural and electronic properties of the AuNCs emitting in the second near-infrared window (NIR-II, 1000-1700 nm). In brief, our model fulfills safety, effectiveness and cost-effectiveness requirements for translational development.

A novel peptide-based three-dimensional probe called "peptide matrix," inspired by the antibody paratope region, was fabricated on a surface plasmon resonance (SPR) sensor chip to enhance the sensitivity of detecting the explosive 2,4,6-trinitrotoluene (TNT). Although peptide aptamer is an attractive candidate for a molecular recognition probe because of its ease of synthesis and chemical stability, it still has difficulty in applying to highly sensitive (i.e. parts-per-billion (ppb) or sub-ppb level) detections. Thus, we developed the concept of peptide matrix structure, which is constructed by consecutive disulfide bond formation between a large number of peptide fragments. This robust three-dimensional structure displays multiple binding sites which can efficiently associate with each TNT molecule. The peptide matrix lowered the dissociation constant (KD) by two orders of magnitude compared to the linear peptide aptamer, estimating KD as 10.1 nM, which is the lowest concentration reported by using peptide-based TNT probe. Furthermore, the concentration limit of detection of peptide matrix modified SPR sensor was 0.62 ppb, and hence comparable to single-chain variable fragment (scFv)-based TNT sensors. To our knowledge, this is the first report demonstrating peptide matrix fabrication and its application for small explosive molecule detection. This peptide matrix-based approach, which has the advantage of simple synthesis and high sensitivity, will be applicable to many other small-molecule label-free detections.

Microbubbles (MBs) are widely used as contrast enhancement agents for ultrasound imaging and have the potential to enhance therapeutic delivery to diseases such as cancer. Yet, they are only stable in solution for a few hours to days after production, which limits their potential application. Freeze-drying provides long-term storage, ease of transport, and consistency in structure and composition, thereby facilitating their use in clinical settings. Therapeutic microbubbles (thMBs) consisting of MBs with attached therapeutic payload potentially face even greater issues for production, stability, and well-defined drug delivery. The ability to freeze-dry thMBs represents an important step for their translation to the clinic. Here, we show that it is possible to freeze-dry and reconstitute thMBs that consist of lipid-coated MBs with an attached liposomal payload. The thMBs were produced microfluidically, and the liposomes contained either calcein, as a model drug, or gemcitabine. The results show that drug-loaded thMBs can be freeze-dried and stored for at least 6 months. Upon reconstitution, they maintain their structural integrity and drug loading. Furthermore, we show that their in vivo echogenicity is maintained post-freeze-drying. Depending on the gas used in the original bubbles, we also demonstrate that the approach provides a method to exchange the gas core to allow the formulation of thMBs with different gases for combination therapies or improved drug efficacy. Importantly, this work provides an important route for the facile off-site production of thMBs that can be reformulated at the point of care.

Most cancer patients receive chemotherapy at some stage of their treatment which makes improving the efficacy of cytotoxic drugs an ongoing and important goal. Despite large numbers of potent anti-cancer agents being developed, a major obstacle to clinical translation remains the inability to deliver therapeutic doses to a tumor without causing intolerable side effects. To address this problem, there has been intense interest in nanoformulations and targeted delivery to improve cancer outcomes. The aim of this work was to demonstrate how vascular endothelial growth factor receptor 2 (VEGFR2)-targeted, ultrasound-triggered delivery with therapeutic microbubbles (thMBs) could improve the therapeutic range of cytotoxic drugs. Methods: Using a microfluidic microbubble production platform, we generated thMBs comprising VEGFR2-targeted microbubbles with attached liposomal payloads for localised ultrasound-triggered delivery of irinotecan and SN38 in mouse models of colorectal cancer. Intravenous injection into tumor-bearing mice was used to examine targeting efficiency and tumor pharmacodynamics. High-frequency ultrasound and bioluminescent imaging were used to visualise microbubbles in real-time. Tandem mass spectrometry (LC-MS/MS) was used to quantitate intratumoral drug delivery and tissue biodistribution. Finally, 89Zr PET radiotracing was used to compare biodistribution and tumor accumulation of ultrasound-triggered SN38 thMBs with VEGFR2-targeted SN38 liposomes alone. Results: ThMBs specifically bound VEGFR2 in vitro and significantly improved tumor responses to low dose irinotecan and SN38 in human colorectal cancer xenografts. An ultrasound trigger was essential to achieve the selective effects of thMBs as without it, thMBs failed to extend intratumoral drug delivery or demonstrate enhanced tumor responses. Sensitive LC-MS/MS quantification of drugs and their metabolites demonstrated that thMBs extended drug exposure in tumors but limited exposure in healthy tissues, not exposed to ultrasound, by persistent encapsulation of drug prior to elimination. 89Zr PET radiotracing showed that the percentage injected dose in tumors achieved with thMBs was twice that of VEGFR2-targeted SN38 liposomes alone. Conclusions: thMBs provide a generic platform for the targeted, ultrasound-triggered delivery of cytotoxic drugs by enhancing tumor responses to low dose drug delivery via combined effects on circulation, tumor drug accumulation and exposure and altered metabolism in normal tissues.

The production and stability of microbubbles (MBs) is enhanced by increasing the viscosity of both the formation and storage solution, respectively. Glycerol is a good candidate for biomedical applications of MBs, since it is biocompatible, although the exact molecular mechanisms of its action is not fully understood. Here, we investigate the influence glycerol has on lipid-shelled MB properties, using a range of techniques. Population lifetime and single bubble stability were studied using optical microscopy. Bubble stiffness measured by AFM compression is compared with lipid monolayer behavior in a Langmuir-Blodgett trough. We deduce that increasing glycerol concentrations enhances stability of MB populations through a 3-fold mechanism. First, binding of glycerol to lipid headgroups in the interfacial monolayer up to 10% glycerol increases MB stiffness but has limited impact on shell resistance to gas permeation and corresponding MB lifetime. Second, increased solution viscosity above 10% glycerol slows down the kinetics of gas transfer, markedly increasing MB stability. Third, above 10%, glycerol induces water structuring around the lipid monolayer, forming a glassy layer which also increases MB stiffness and resistance to gas loss. At 30% glycerol, the glassy layer is ablated, lowering the MB stiffness, but MB stability is further augmented. Although the molecular interactions of glycerol with the lipid monolayer modulate the MB lipid shell properties, MB lifetime continually increases from 0 to 30% glycerol, indicating that its viscosity is the dominant effect on MB solution stability. This three-fold action and biocompatibility makes glycerol ideal for therapeutic MB formation and storage and gives new insight into the action of glycerol on lipid monolayers at the gas-liquid interface.

There is a significant drive to identify alternative materials that exhibit room temperature phosphorescence for technologies including bio-imaging, photodynamic therapy and organic light-emitting diodes. Ideally, these materials should be non-toxic and cheap, and it will be possible to control their photoluminescent properties. This was achieved here by embedding carbon nanodots within crystalline particles of alkaline earth carbonates, sulphates and oxalates. The resultant nanocomposites are luminescent and exhibit a bright, sub-second lifetime afterglow. Importantly, the excited state lifetimes, and steady-state and afterglow colours can all be systematically controlled by varying the cations and anions in the host inorganic phase, due to the influence of the cation size and material density on emissive and non-emissive electronic transitions. This simple strategy provides a flexible route for generating materials with specific, phosphorescent properties and is an exciting alternative to approaches relying on the synthesis of custom-made luminescent organic molecules.

The functionalization of small diameter (ca. 50 nm) polycarboxylated nanodiamond particles using amide coupling methodologies in both water and acetonitrile solvent has been investigated. In this manner, the surfaces of nanodiamond particles were adorned with different luminescent moieties, including a green fluorescent 1,8-naphthalimide species (Nap-1), and a red emitting ruthenium(II) trisbipyridine complex (Ru-1), as well as dual functionalization with both luminophores. Comprehensive characterization of the surface functionalized nanodiamonds has been achieved using a combination of dynamic light scattering, nanoparticle tracking analysis, transmission electron microscopy, X-ray photoelectron spectroscopy, zeta potential measurements, microwave plasma atomic emission spectroscopy and time-resolved photophysics. The tendency of the functionalized nanodiamonds to aggregate reflects the degree of surface substitution, yielding small aggregates with typical particle sizes ca. 150 nm. This is likely to be driven by the reduction of the zeta potential, concomitant with the conversion of surface charged carboxylate groups to neutral amide functions. The results show that luminescent nanodiamond materials can be synthesised with tuneable photophysical properties. (C) 2019 Elsevier Ltd. All rights reserved.

Iron sulfur (Fe–S) phases have been implicated in the emergence of life on early Earth due to their catalytic role in the synthesis of prebiotic molecules. Similarly, Fe–S phases are currently of high interest in the development of green catalysts and energy storage. Here we report the synthesis and structure of a nanoparticulate phase (FeS nano ) that is a necessary solid-phase precursor to the conventionally assumed initial precipitate in the iron sulfide system, mackinawite. The structure of FeS nano contains tetrahedral iron, which is compensated by monosulfide and polysulfide sulfur species. These together dramatically affect the stability and enhance the reactivity of FeS nano .

Lipid tubules are of particular interest for many potential applications in nanotechnology. Among various lipid tubule fabrication techniques, the morphological regulation of membrane structure by proteins mimicking biological processes may provide the chances to form lipid tubes with highly tuned structures. Magnetotactic bacteria synthesize magnetosomes (a unique prokaryotic organelle comprising a magnetite crystal within a lipid envelope). MamY protein is previously identified as the magnetosome protein responsible for magnetosome vesicle formation and stabilization. Furthermore, MamY is shown in vitro liposome tubulation activity. In this study, the interaction of MamY and phospholipids is investigated by using a lipids-immobilized membrane strip and a peptide array. Here, the binding of MamY to the anionic phospholipid, cardiolipin, is found and enhanced liposome tubulation efficiency. The authors propose the interaction is responsible for recruiting and locating cardiolipin to elongate liposome in vitro. The authors also suggest a similar mechanism for the invagination site in magnetosomes vesicle formation, where the lipid itself contributes further to increasing the curvature. These findings are highly important to develop an effective biomimetic synthesis technique of lipid tubules and to elucidate the unique prokaryotic organelle formation in magnetotactic bacteria.